A Biomarker Dialogue Between Patient and Scientist

HOST: Hildy Grossman, CO-HOST: Jordan Rich

GUEST: Marc Muskavitch, PhD, ALK+ & Zachary Rogers, PhD, Research Fellow, Koch Institute at MIT

This episode features a powerful conversation between two scientists, one now navigating life as a Stage 4 ALK+ lung cancer patient. Most lung cancer patients only learn the significance of biomarkers like ALK+, soon after their diagnosis. Our guest Marc Muskavitch, however, arrived at this knowledge with a distinct advantage: he is a scientist himself. With a background spanning drug development, biochemistry, and genetics, and holding seventeen patents, Marc’s understanding shaped his emotional and strategic response to his diagnosis and ongoing journey. His compelling conversation with scientist Zach Rogers, a previous podcast guest who addressed recurrence and drug response in lung cancer, gains even greater meaning in this context. Marc also sheds light on the significant community brought together by the ALK Positive patient organization that is now collaborating with the scientific research organization, Break Through Cancer. Our guests discuss their vision for hopeful future advancements in cancer treatment.